Drugs / HBI-2438
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05485974 | Aug 2022 → Dec 2026 expected | colon carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma | HUYABIO International, LLC. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBI-2438 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05485974 ↗ |
| Action | Inhibit | “KRAS G12C Inhibitor” NCT05485974 ↗ |
| Route | Oral | “orally administered” NCT05485974 ↗ |
| Target | KRAS | “KRAS G12C Inhibitor” NCT05485974 ↗ |